Published in J Immunol on June 15, 2000
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol (2003) 11.48
The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci (2011) 1.35
Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol (2007) 1.30
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2010) 1.24
pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano (2013) 1.13
Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction. J Virol (2002) 1.13
Secreted immunodominant Mycobacterium tuberculosis antigens are processed by the cytosolic pathway. J Immunol (2010) 1.01
Link between organ-specific antigen processing by 20S proteasomes and CD8(+) T cell-mediated autoimmunity. J Exp Med (2002) 1.00
The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome. Mol Cell Proteomics (2013) 0.89
Oxidants and Ca+2 induce PGC-1alpha degradation through calpain. Arch Biochem Biophys (2008) 0.84
Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol (2003) 0.83
Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I. Virology (2008) 0.81
Proteasome-mediated proteolysis of SRSF5 splicing factor intriguingly co-occurs with SRSF5 mRNA upregulation during late erythroid differentiation. PLoS One (2013) 0.81
The degradation pathway for the HBV envelope proteins involves proteolysis prior to degradation via the cytosolic proteasome. Virology (2007) 0.80
Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope. Immunology (2009) 0.80
Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers. J Neurooncol (2006) 0.80
Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response. EMBO Mol Med (2014) 0.80
Allele-dependent processing pathways generate the endogenous human leukocyte antigen (HLA) class I peptide repertoire in transporters associated with antigen processing (TAP)-deficient cells. J Biol Chem (2011) 0.78
Antigen processing and immune regulation in the response to tumours. Immunology (2016) 0.75
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. Blood Cancer J (2016) 0.75
Development of Small Molecular Proteasome Inhibitors Using a Caenorhabditis elegans Screen. Int J Med Chem (2014) 0.75
Apolipoprotein A-I gene transfer exerts immunomodulatory effects and reduces vascular inflammation and fibrosis in ob/ob mice. J Inflamm (Lond) (2016) 0.75
Structure of 20S proteasome from yeast at 2.4 A resolution. Nature (1997) 12.73
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 11.73
The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem (1999) 8.97
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A (1999) 5.28
Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol (1999) 3.99
Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J Virol Methods (1991) 3.78
LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol (1994) 3.47
Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med (1998) 3.03
Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol (1996) 2.88
The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem (1997) 2.85
Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med (1988) 2.85
Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem (1997) 2.39
Lactacystin, proteasome function, and cell fate. J Biol Chem (1998) 2.33
A giant protease with potential to substitute for some functions of the proteasome. Science (1999) 2.08
Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol (1991) 1.96
Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J Antibiot (Tokyo) (1991) 1.86
The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J Biol Chem (1995) 1.70
DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol (1997) 1.69
Protein-protein interactions in lymphocytic choriomeningitis virus. Virology (1991) 1.68
Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today (1996) 1.65
Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell (1999) 1.58
Cytolytic T lymphocyte recognition of the murine cytomegalovirus nonstructural immediate-early protein pp89 expressed by recombinant vaccinia virus. J Exp Med (1987) 1.57
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett (1999) 1.54
The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol (1997) 1.51
Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem Biol (1998) 1.51
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A (1998) 1.50
Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization. Virology (1983) 1.49
Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo) (1992) 1.44
Restoration of H-2b expression and processing of endogenous antigens in the MHC class I pathway by fusion of a lymphoma mutant to L cells of the H-2k haplotype. Eur J Immunol (1990) 1.29
Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem Biophys Res Commun (1997) 1.26
Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER. Immunity (1999) 1.19
Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med (1999) 1.14
The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: involvement of nonproteasomal cytosolic proteases in antigen processing? J Immunol (1997) 1.10
How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem (1999) 1.07
IFN-gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase. J Immunol (1999) 1.02
Thimet oligopeptidase (EC 3.4.24.15), a novel protein on the route of MHC class I antigen presentation. Biochem Biophys Res Commun (1999) 1.02
Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. J Exp Med (1998) 0.98
Comparison of the sensitivity of in vivo and in vitro assays for detection of antiviral cytotoxic T cell activity. Cell Immunol (1993) 0.97
CTL epitope generation is tightly linked to cellular proteolysis of a Listeria monocytogenes antigen. J Immunol (1996) 0.94
Inactivation of a defined active site in the mouse 20S proteasome complex enhances major histocompatibility complex class I antigen presentation of a murine cytomegalovirus protein. J Exp Med (1998) 0.91
The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules. J Immunol (1997) 0.90
Selective proteasome inhibitors: modulators of antigen presentation? Drug Discov Today (1999) 0.88
Allelic differences in the relationship between proteasome activity and MHC class I peptide loading. J Immunol (1998) 0.88
Immunodominant T cell epitope from signal sequence. Science (1992) 0.87
Generation of naturally processed peptide/MHC class I complexes is independent of the stability of endogenously synthesized precursors. J Immunol (1996) 0.86
Mutational analysis of subunit i beta2 (MECL-1) demonstrates conservation of cleavage specificity between yeast and mammalian proteasomes. FEBS Lett (1999) 0.86
The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Mol Immunol (1998) 0.81
The use of LCMV-specific T cell hybridomas for the quantitative analysis of MHC class I restricted antigen presentation. J Immunol Methods (2000) 0.77
Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor. Cell (1997) 6.28
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature (1999) 5.76
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A (1999) 5.28
Two different subunits of importin cooperate to recognize nuclear localization signals and bind them to the nuclear envelope. Curr Biol (1995) 4.46
Posttranslational protein transport in yeast reconstituted with a purified complex of Sec proteins and Kar2p. Cell (1995) 3.46
Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med (2000) 3.26
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A (1997) 3.23
Analysis and expression of a cloned pre-T cell receptor gene. Science (1994) 2.66
Importin provides a link between nuclear protein import and U snRNA export. Cell (1996) 2.65
A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J (1998) 2.43
COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J (2001) 2.41
The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol (2001) 2.41
Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A (2001) 2.39
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol (1999) 2.22
Exportin 4: a mediator of a novel nuclear export pathway in higher eukaryotes. EMBO J (2000) 2.18
The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev (2001) 2.18
Diagnostic value of the radioisotope erection penogram for vasculogenic impotence. J Urol (1990) 2.05
A tetrameric complex of membrane proteins in the endoplasmic reticulum. Eur J Biochem (1993) 2.04
Low versus high cell turnover in diffusely growing non-Hodgkin's lymphomas. J Pathol (1995) 2.03
Reconstitution of the Raf-1-MEK-ERK signal transduction pathway in vitro. Mol Cell Biol (1993) 1.99
Importin 13: a novel mediator of nuclear import and export. EMBO J (2001) 1.98
Sequence and expression of chicken and mouse rsk: homologs of Xenopus laevis ribosomal S6 kinase. Mol Cell Biol (1989) 1.96
Malignant cells are collected on circular staplers. Dis Colon Rectum (1992) 1.94
Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science (1998) 1.94
Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. Proc Natl Acad Sci U S A (1992) 1.82
Phorbol ester stimulates a protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product. Proc Natl Acad Sci U S A (1992) 1.81
Sm protein-Sm site RNA interactions within the inner ring of the spliceosomal snRNP core structure. EMBO J (2001) 1.79
Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell (1996) 1.76
Structure and function of a periplasmic nitrate reductase in Alcaligenes eutrophus H16. J Bacteriol (1993) 1.69
Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J Immunol (2001) 1.66
Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones. Chem Biol (1999) 1.65
Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J Exp Med (1998) 1.65
Association of the subtype 2 of the Epstein-Barr virus with T-cell non-Hodgkin's lymphoma of the midline granuloma type. Blood (1993) 1.63
Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene (2008) 1.59
MAPKAP kinase 2 phosphorylates serum response factor in vitro and in vivo. J Biol Chem (1999) 1.58
Preferential positive selection of V alpha 2+ CD8+ T cells in mouse strains expressing both H-2k and T cell receptor V alpha a haplotypes: determination with a V alpha 2-specific monoclonal antibody. Eur J Immunol (1992) 1.58
A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity (1996) 1.58
At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. Genomics (1989) 1.55
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett (1999) 1.54
Diffuse centrocytic and/or centroblastic malignant non-Hodgkin's lymphomas: comparison of mitotic and pyknotic (apoptotic) indices. Int J Cancer (1991) 1.53
Analysis of mammalian 20S proteasome biogenesis: the maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis. EMBO J (1996) 1.53
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A (1998) 1.50
Tailored lay health worker intervention improves breast cancer screening outcomes in non-adherent Korean-American women. Health Educ Res (2008) 1.49
Restoration of atrial mechanical function after maze operation in patients with structural heart disease. Am Heart J (1998) 1.48
Novel genes coding for lithotrophic sulfur oxidation of Paracoccus pantotrophus GB17. J Bacteriol (2000) 1.47
Mammalian Sec61 is associated with Sec62 and Sec63. J Biol Chem (2000) 1.47
The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J Biol Chem (2001) 1.46
Full-length rat alpha and beta cardiac myosin heavy chain sequences. Comparisons suggest a molecular basis for functional differences. J Mol Biol (1989) 1.46
Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis (2001) 1.46
A general approach for identification of RNA-protein cross-linking sites within native human spliceosomal small nuclear ribonucleoproteins (snRNPs). Analysis of RNA-protein contacts in native U1 and U4/U6.U5 snRNPs. J Biol Chem (2000) 1.45
Raf-1 forms a stable complex with Mek1 and activates Mek1 by serine phosphorylation. Proc Natl Acad Sci U S A (1993) 1.44
Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. J Immunol (2000) 1.44
Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J Immunol (2001) 1.44
Majority of hMLH1 mutations responsible for hereditary nonpolyposis colorectal cancer cluster at the exonic region 15-16. Am J Hum Genet (1996) 1.43
Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol (1993) 1.43
Incorporation of major histocompatibility complex--encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. Eur J Immunol (1995) 1.40
Late results in patients treated with pi-mesons for bladder cancer. Cancer (1993) 1.39
The signal sequence receptor has a second subunit and is part of a translocation complex in the endoplasmic reticulum as probed by bifunctional reagents. J Cell Biol (1990) 1.35
A third interferon-gamma-induced subunit exchange in the 20S proteasome. Eur J Immunol (1996) 1.35
Role of virus and host variables in virus persistence or immunopathological disease caused by a non-cytolytic virus. J Gen Virol (1995) 1.34
Eponemycin analogues: syntheses and use as probes of angiogenesis. Bioorg Med Chem (1998) 1.34
Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Mol Cell (2001) 1.34
The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci U S A (2000) 1.33
The growth-related protein P23 of the Ehrlich ascites tumor: translational control, cloning and primary structure. Biochem Int (1989) 1.33
Molecular cloning, sequencing and expression in Escherichia coli of the 25-kDa growth-related protein of Ehrlich ascites tumor and its homology to mammalian stress proteins. Eur J Biochem (1989) 1.31
Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res (1999) 1.31
Seven new mutations in hMSH2, an HNPCC gene, identified by denaturing gradient-gel electrophoresis. Am J Hum Genet (1995) 1.30
Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol (1994) 1.29